Publication Name	World Journal of Gastroenterology
Manuscript ID	9617
Country	China

Received	2014-02-20 14:35
Peer-Review Started	2014-02-20 21:51
To Make the First Decision	2014-03-13 18:56
Return for Revision	2014-03-20 08:46
Revised	2014-04-08 23:00
Second Decision	2014-05-19 15:23
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-05-19 15:30
Articles in Press	2014-05-23 10:32
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-06-03 15:05
Typeset the Manuscript	2014-08-01 10:07
Publish the Manuscript Online	2014-08-20 18:38

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Study
Article Title	Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma
Manuscript Source	Unsolicited Manuscript
All Author List	Jie Wu, Lei Song, Dan-Yi Zhao, Bing Guo and Jing Liu
Funding Agency and Grant Number
Corresponding Author	Lei Song, MS, Department of Medical Oncology, the Second Hospital of Dalian Medical University, Zhongshan Road 467, Dalian 116023, Liaoning Province, China. songlei_1975@126.com
Key Words	Irinotecan; Gemcitabine; Transarterial chemoembolization; Hepatocellular carcinoma; Overall survival
Core Tip	In the present study, we aimed to compare the efficacy of different chemotherapeutic agents during conventional transarterial chemoembolization (cTACE) in the treatment of unresectable hepatocellular carcinoma. Our study indicated that for patients treated with cTACE, the chemotherapeutic agent irinotecan (CPT-11) was significantly associated with improved overall survival and longer time to progression compared with gemcitabine or doxorubicin. There were no significant differences in clinical adverse events between the three agents. CPT-11 thus appears to be a promising agent when combined with cTACE for the treatment of hepatocellular carcinoma.
Publish Date	2014-08-20 18:38
Citation	Wu J, Song L, Zhao DY, Guo B, Liu J. Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2014; 20(31): 10960-10968
URL	http://www.wjgnet.com/1007-9327/full/v20/i31/10960.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i31.10960

Full Article (PDF)	WJG-20-10960.pdf
Full Article (Word)	WJG-20-10960.doc
Manuscript File	9617-Review.doc
Answering Reviewers	9617-Answering reviewers.pdf
Copyright License Agreement	9617-Copyright Assignment.pdf
Non-Native Speakers of English Editing Certificate	9617-Language certificate.pdf
Peer-review Report	9617-Peer review.pdf
Scientific Editor Work List	9617-Scientific editor work list.pdf